Marseille

• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpo … Recruiting
  2024-513811-29-00 5 2023-07-03 Cardiogenic Shock
• Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren … Recruiting
  2024-512999-35-00 4 2023-06-23 Patients with HER 2 negative locally advanced, recurrent or metastatic
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Recruiting
  2022-502415-11-00 5 2023-06-16 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• Early phase study to evaluate the safety and efficacy of SMART101 to improve transplantation in blood cancers Recruiting
  2024-517953-28-00 7 2023-06-07 Treatment in haematopoietic stem cell transplantation
• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in R/R PCNSL Recruiting
  2024-513312-95-00 7 2023-05-30 Part B+C. Primary central nervous system lymphoma (PCNSL)
• A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting
  2023-504263-16-00 5 2023-05-25 This is an extension study designed to provide continued treatment for
• Evaluation of diagnostic performances of 18F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliom … Recruiting
  2022-501688-42-00 5 2023-05-24 Low Grade Glioma
• RIISC Recruiting
  2024-513669-38-00 5 2023-05-17 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial In
• PROPHYLOXITIN-Intermittent cefoxitin administration versus loading bolus followed by continuous infusion for the prevention of surgical site … Recruiting
  2024-515146-16-00 5 2023-05-15 Colorectal surgery
• First-in-human study of OT-A201 in patients with selected hematological malignancies and solid tumors Recruiting
  2024-511936-28-00 1 2023-05-12 Relapsed/refractory hematological malignancies or advanced/metastatic
• Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx) Recruiting
  2022-501133-23-00 4 2023-05-11 MIGRAINE
• Sotatercept in Children with Pulmonary Artery Hypertension on Standard of Care Recruiting
  2023-504861-22-00 4 2023-05-05 Pulmonary arterial hypertension
• EDEN : Etude de désescalade thérapeutique et d'évaluation du marqueur miRNA M371 pour les séminomes de stade IIa/IIb < 3 cm Recruiting
  2024-514636-25-00 4 2023-05-04 Stage IIa/IIb < 3 cm seminoma
• A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refra … Recruiting
  2023-504897-39-00 1 2023-04-13 Advanced or refractory solid tumours (Part 1)
• A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06)) Recruiting
  2023-505040-19-00 4 2023-04-11 Non-seminomatous germ-cell tumors (including testis, retroperitoneal a
• THINK - intensification of blood pressure lowering Therapeutics based on diuretics versus usual management for uncontrolled Hypertension IN … Recruiting
  2022-501494-39-00 5 2023-03-28 Uncontrolled Hypertension IN patients with moderate to severe chronic
• REVERT : REVErsing airway Remodelling with Tezepelumab Recruiting
  2024-513195-18-00 5 2023-03-27 Severe asthma
• A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua … Recruiting
  2022-501238-52-00 10 2023-03-23 Heart failure due to systemic left ventricular systolic dysfunction
• A study investigating the use of EP0031 in patients with cancers having an abnormal RET gene. Recruiting
  2022-501636-42-00 9 2023-03-21 Advanced RET-altered malignancies
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting
  2023-503481-23-00 5 2023-03-20 Maintenance treatment in metastatic non-squamous lung cancer
• Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting
  2023-507778-42-00 4 2023-03-08 Non-Small Cell Lung Cancer II, III
• A RANDOMIZED DOUBLE BLIND, PLACEBO-CONTROLLED NATIONAL MULTICENTER PHASE 3 TRIAL TO EVALUATE THE EFFICACY OF AZATHIOPRINE FOR THE PREVENTION … Recruiting
  2022-500520-30-00 5 2023-03-01 neurology

Showing 673–696 of 1,485 trials